title: High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France.
abstract: We retrospectively evaluated the feasibility and antitumour efficacy of high dose melphalan (HDM) followed by autologous marrow rescue in 35 patients with common epithelial ovarian cancers. All patients initially had advanced disease (FIGO III-IV) and received HDM after extensive surgery and a median of 6 cycles of cis-DDP containing regimens CAP or CHAP. All, except three patients who showed evidence of progression, had a second surgical exploration before high dose chemotherapy. Melphalan was given at a dosage greater than or equal to 140 mg/m2 followed 24 h later by autologous marrow rescue. Severe but reversible aplasia and mucositis were the most common toxicities: three patients died from the procedure, two from infection and one from secondary leukaemia. HDM was effective in 75% of evaluable patients; this was evidence of activity in patients who failed to respond to first line chemotherapy. The duration of response was short, particularly for patients treated with progressive disease at the time of high dose chemotherapy rather than in partial or complete remission. With a median follow-up of 23 months (range 8-54) after high dose chemotherapy, 19 patients are alive (15 with non-progressive disease) with a projected survival of 47% between 2 and 5 years.
authors.affiliation: Marrow Transplant Unit, Institut Paoli Calmettes, Marseille, France.
authors.forename: P
authors.initials: P
authors.lastname: Viens
authors.forename: D
authors.initials: D
authors.lastname: Maraninchi
authors.forename: M
authors.initials: M
authors.lastname: Legros
authors.forename: F
authors.initials: F
authors.lastname: Oberling
authors.forename: T
authors.initials: T
authors.lastname: Philip
authors.forename: P
authors.initials: P
authors.lastname: Herve
authors.forename: R
authors.initials: R
authors.lastname: Plagne
authors.forename: P
authors.initials: P
authors.lastname: Dufour
authors.forename: J P
authors.initials: JP
authors.lastname: Bergerat
authors.forename: J P
authors.initials: JP
authors.lastname: Guastalla
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D002277:Carcinoma / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery; D004305:Dose-Response Relationship, Drug; D005260:Female; D005602:France; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use* / Q000633:toxicity; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery; D011379:Prognosis; D012189:Retrospective Studies; D014182:Transplantation, Autologous
chemical_list: D008558:Melphalan